Table 2

Eligible study protocols

IdentifierCountryStudy designArmsInterventionComparisonSample sizeFollow-up period
NCT04357730USARCT2 armsAlteplaseStandard of care5028 days
NCT04640194Austria, Belgium, Brazil, Denmark France, Germany, Italy, Netherlands, Portugal, Russian Federation, SpainRCT3 armsAlteplase (low dose) on top of standard of care
Alteplase (high dose) on top of standard of care
Standard of care32028 days
NCT04505592USARCT2 armsTenecteplasePlacebo6028 days
IRCT20200415047080N1IranRCT2 armsAlteplaseStandard of care3028 days
IRCT20200515047456N1IranRCT3 armsrtPAStandard of care1530 days
  • RCT, randomised controlled trial; rtPA, recombinant tissue plasminogen activator.